185 related articles for article (PubMed ID: 27896637)
1. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016).
Vera R; Dotor E; Feliu J; González E; Laquente B; Macarulla T; Martínez E; Maurel J; Salgado M; Manzano JL
Clin Transl Oncol; 2016 Dec; 18(12):1172-1178. PubMed ID: 27896637
[TBL] [Abstract][Full Text] [Related]
2. Current standards and new innovative approaches for treatment of pancreatic cancer.
Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M
Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397
[TBL] [Abstract][Full Text] [Related]
3. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
di Sebastiano P; Grottola T; di Mola FF
Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
[TBL] [Abstract][Full Text] [Related]
4. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
Yoo C; Kang J; Kim KP; Lee JL; Ryoo BY; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Kim SC
Oncotarget; 2017 Jul; 8(28):46337-46347. PubMed ID: 28564637
[TBL] [Abstract][Full Text] [Related]
6. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.
Benavides M; Abad A; Ales I; Carrato A; Díaz Rubio E; Gallego J; García-Foncillas J; Grávalos C; Laquente B; Pericay C; Rivera F; Tabernero J; Aranda E
Clin Transl Oncol; 2014 Oct; 16(10):865-78. PubMed ID: 24728654
[TBL] [Abstract][Full Text] [Related]
7. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
[TBL] [Abstract][Full Text] [Related]
8. [Adjuvant Chemotherapy after Surgery for Pancreatic Cancer].
Furuse J
Gan To Kagaku Ryoho; 2016 Feb; 43(2):160-4. PubMed ID: 27067680
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
[TBL] [Abstract][Full Text] [Related]
10. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases.
Wang G; Zhou D
Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389
[TBL] [Abstract][Full Text] [Related]
11. Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research.
Buanes TA
World J Gastroenterol; 2016 Dec; 22(48):10502-10511. PubMed ID: 28082802
[TBL] [Abstract][Full Text] [Related]
12. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC).
Neuzillet C; Gaujoux S; Williet N; Bachet JB; Bauguion L; Colson Durand L; Conroy T; Dahan L; Gilabert M; Huguet F; Marthey L; Meilleroux J; de Mestier L; Napoléon B; Portales F; Sa Cunha A; Schwarz L; Taieb J; Chibaudel B; Bouché O; Hammel P; ; ; ; ; ; ; ; ; ;
Dig Liver Dis; 2018 Dec; 50(12):1257-1271. PubMed ID: 30219670
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant treatment for pancreatic ductal carcinoma.
Macarulla T; Fernández T; Gallardo ME; Hernando O; López AM; Hidalgo M
Clin Transl Oncol; 2017 Oct; 19(10):1199-1204. PubMed ID: 28639051
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy of pancreatic cancer.
Hilbig A; Oettle H
Expert Rev Anticancer Ther; 2010 Apr; 10(4):485-91. PubMed ID: 20397913
[TBL] [Abstract][Full Text] [Related]
16. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
[TBL] [Abstract][Full Text] [Related]
17. Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature.
Oneda E; Zaniboni A
J Clin Med; 2019 Nov; 8(11):. PubMed ID: 31717439
[TBL] [Abstract][Full Text] [Related]
18. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
19. The role of neoadjuvant therapy in pancreatic cancer: a review.
Russo S; Ammori J; Eads J; Dorth J
Future Oncol; 2016 Mar; 12(5):669-85. PubMed ID: 26880384
[TBL] [Abstract][Full Text] [Related]
20. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
